Guardant Health Reports Q3 2026 Results, Raises Revenue Guidance
Guardant Health reported results for the quarter ended September 30, 2026, and increased its 2026 revenue guidance.
Story updates
09:08:22 PM UTC
SquawkNews
Q3 2026 revenue rose 36% year over year to $361.0M from $265.2M. Guardant Health raised its 2026 revenue outlook to $1.36B—$1.37B from $1.34B—$1.36B, while increasing expected free cash flow burn to $205M—$220M from $195M—$205M.Material DetailsContext by AI AnalystThis is a mid-cycle growth update…
Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today reported financial results for the quarter ended September 30, 2026.Third Quarter 2026 Financial HighlightsFor the three-month period ended September 30, 2026, as compared to the same period of 2025:Recent Operating High…